RecruitingPhase 3NCT06174766

A Study to Evaluate Efficacy and Safety of HGP2102 in Essential Hypertension Patients

A Multicenter, Randomized, Double-blind, Phase 3 Study to Evaluate Efficacy and Safety of HGP2102 in Patients With Essential Hypertension


Sponsor

Hanmi Pharmaceutical Company Limited

Enrollment

324 participants

Start Date

May 10, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

A Multicenter, Randomized, Double-blind, Phase 3 Study to Evaluate the Efficacy and Safety of HGP2102 in patients with Essential Hypertension


Eligibility

Min Age: 19 Years

Plain Language Summary

Simplified for easier understanding

This trial is testing HGP2102, a new drug candidate for essential tremor — a neurological condition that causes uncontrollable shaking, most commonly in the hands — in people for whom current medications haven't worked well enough. **You may be eligible if...** - You are an adult with a diagnosed essential tremor that significantly affects your daily life - Your tremor has not been adequately controlled with existing medications - You are otherwise in good health and able to attend study visits **You may NOT be eligible if...** - Your tremor is caused by another condition (like Parkinson's disease or medication side effects) - You are on other tremor medications that cannot be adjusted - You have significant liver, kidney, or heart problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGHGP2102-1

Test drug

DRUGHGP2102-2

Test drug

DRUGRLD2209-1

Control drug

DRUGRLD2209-2

Control drug


Locations(1)

Sevrance hosptal

Seodaemun-gu, Seoul, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06174766


Related Trials